Immunogenicity of the Novel Glucagon Analogue Dasiglucagon: Results of a Dedicated Immunogenicity Trial in Type 1 Diabetes

Immunogenicity of the Novel Glucagon Analogue Dasiglucagon: Results of a Dedicated Immunogenicity Trial in Type 1 Diabetes

Dasiglucagon is a next-generation glucagon analogue that is stable in aqueous formulation. This dedicated immunogenicity trial to support use as rescue treatment for severe hypoglycemia was conducted to evaluate the immunogenicity of repeated subcutaneous doses of dasiglucagon in subjects with type...

Full description

Bibliographic Details
Main Authors: Ajala, O. (Author), Dahl, D. (Author), Hansen, L.E (Author), Pieber, T.R (Author), Steen, O. (Author), Tehranchi, R. (Author)
Format: Article
Language:English
Published: Mary Ann Liebert Inc. 2021
Subjects:
adult
antibody screening
Article
Blood Glucose
blood glucose monitoring
body mass
controlled study
cross reaction
dasiglucagon
Dasiglucagon
Diabetes Mellitus, Type 1
direct ELISA
disease duration
double blind procedure
Double-Blind Method
drug antibody
drug safety
enzyme linked immunosorbent assay
female
glucagon
Glucagon
glucose
glucose blood level
hemoglobin A1c
human
Humans
hypoglycemia
Hypoglycemia
immunogenicity
Immunogenicity
immunoglobulin G antibody
immunoglobulin M antibody
insulin dependent diabetes mellitus
insulin derivative
insulin infusion
insulin treatment
long acting insulin
major clinical study
male
multicenter study
nausea and vomiting
neutralization test
neutralizing antibody
randomized controlled trial
Randomized trial
recombinant glucagon
short acting insulin
Type 1 diabetes
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items